Explore the words cloud of the GNA NOW project. It provides you a very rough idea of what is the project "GNA NOW" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||31˙415˙987 €|
|EC max contribution||12˙299˙995 € (39%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-07-01 to 2025-06-30|
Take a look of project's partnership.
|1||STICHTING LYGATURE||NL (UTRECHT)||coordinator||620˙681.00|
|2||NOSOPHARM||FR (LYON CEDEX 03)||participant||4˙069˙500.00|
|3||NORTH BRISTOL NATIONAL HEALTH SERVICE TRUST||UK (BRISTOL)||participant||2˙422˙556.00|
|4||MEDIZINISCHE UNIVERSITAET WIEN||AT (WIEN)||participant||1˙495˙300.00|
|5||HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH||DE (BRAUNSCHWEIG)||participant||1˙268˙750.00|
|6||ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM||NL (ROTTERDAM)||participant||1˙198˙125.00|
|7||THE UNIVERSITY OF LIVERPOOL||UK (LIVERPOOL)||participant||430˙523.00|
|8||BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE||FR (LYON)||participant||308˙896.00|
|9||FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.||DE (MUNCHEN)||participant||300˙000.00|
|10||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||participant||185˙662.00|
|11||EVOTEC INTERNATIONAL GMBH||DE (HAMBURG)||participant||0.00|
AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.
Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GNA NOW" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GNA NOW" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More
Antibiotic Distribution and Recovery in TissueRead More